|
시장보고서
상품코드
2032662
파이로젠 시험 시장 보고서 : 제품별, 시험 유형별, 용도별, 지역별(2026-2034년)Pyrogen Testing Market Report by Product (Instruments, Kits and Reagents, Services), Test Type (In-vitro Tests, LAL Tests, Rabbit Tests, and Others), Application (Pharmaceutical and Biologics, Medical Devices, and Others), and Region 2026-2034 |
||||||
세계의 파이로젠 시험 시장 규모는 2025년에 16억 달러에 달했습니다. 향후, IMARC Group은 2034년까지 시장 규모가 34억 달러에 이르고, 2026-2034년 CAGR은 8.36%를 나타낼 것으로 예측했습니다. 이 시장은 세계 제약 및 바이오테크놀러지 산업의 성장, 심장병, 암, 당뇨병과 같은 만성질환의 유병률 증가, 신약 출시 및 연구개발(R&D) 활동에 대한 자금 투입 증가에 힘입어 성장하고 있습니다.
규제 준수 및 안전 기준
파이로젠 시험 시장의 성장은 미국 식품의약국(FDA)과 유럽의 유럽의약품청(EMA)과 같은 보건 당국의 엄격한 규제 프레임워크 도입에 의해 크게 견인되고 있습니다. AAMI ST72; 2002/R2010, "세균성 내독소 - 조사 방법, 일상적 모니터링 및 배치 시험의 대안(AAMI ST72)"은 겔 응고법, 광도법 및 동적 시험법의 기본 원리를 기술한 문서로, 적절한 구성품 및 완제품에 대해 구성품 및 완제품에 대해 파이로젠 및 내독소 존재 여부를 검사할 것을 권장하고 있습니다. 이러한 규정은 발열을 유발하고 환자에게 심각한 위험을 초래할 수 있는 발열 물질이 포함되어 있지 않도록 의약품, 의료기기 및 생물학적 제제에 대한 엄격한 안전성 시험를 요구하고 있습니다. 그 결과, 제조업체들은 생산 공정에 발열 물질 시험를 도입하고 있습니다.
제약 및 생명공학 산업의 발전
제약 및 생명공학 분야의 성장과 생물학적 제제 생산 증가도 파이로젠 시험 시장 전망을 밝게 하고 있습니다. 생물 유래 생물학적 제제는 파이로젠에 의한 오염에 취약한 특성이 있습니다. IMARC GROUP에 따르면, 세계 생물학적 제제 시장 규모는 2023년 3,496억 달러에 달했습니다. 향후 파이로젠 시험 시장 규모는 2032년까지 6,995억 달러에 달할 것으로 예상되며, 2024년부터 2032년까지 연평균 복합 성장률(CAGR) 7.8%를 나타낼 것으로 예측됩니다. 이러한 산업이 확대됨에 따라, 고도로 신뢰할 수 있고 신속한 파이로젠 시험에 대한 수요도 증가하고 있습니다. 또한, 이러한 수요는 기존의 꽃게 혈액 유래 검사를 대체할 수 있는 합성 대체법인 재조합 인자 C(rFC) 분석과 같은 검사 기술의 혁신으로 이어지고 있습니다.
의료 인프라 정비
신흥국의 의료 인프라 정비와 발열물질 프리 인증을 포함한 국제 안전기준을 충족하는 의료제품에 대한 수요 증가로 발열물질 시험에 대한 수요가 증가하고 있습니다. 이러한 확대는 발열 물질 시험의 지리적 시장을 넓히고, 현지 제조업체들이 세계 시장에 진출하기 위해 첨단 시험 기술을 채택하도록 장려하고 있습니다. 또한, 의료 시스템의 발전과 의료비 증가로 인해 첨단 발열 물질 시험 프로세스의 도입과 통합이 진행되고 있습니다. 또한, 정부 당국도 공중 보건을 증진하기 위해 의료 산업에 투자하고 있습니다. 예를 들어, 미국 질병통제예방센터(CDC)는 미국 전역의 주, 지방정부 및 준주정부가 공중보건 인력과 인프라를 강화할 수 있도록 32억 달러의 보조금을 지원했습니다. 이 32억 달러에는 '미국구조계획법(American Rescue Plan Act)에 따른 30억 달러가 포함되어 있으며, 각 관할 구역이 역학조사관, 접촉자 추적자, 검사관, 지역보건요원, 데이터 분석가 등 중요한 일선 공중보건 인력을 채용, 유지, 육성하는 데 활용될 예정입니다. 채용, 유지, 육성하는 데 활용됩니다. 또한, 이 기금에는 각 관할 구역이 공중보건 인프라를 강화하고 활성화하기 위한 신규 예산 1억 4,000만 달러도 포함되어 있습니다.
The global pyrogen testing market size reached USD 1.6 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 3.4 Billion by 2034, exhibiting a growth rate (CAGR) of 8.36% during 2026-2034. The market is propelled by the expanding pharmaceutical and biotechnology industries around the world, the increasing prevalence of chronic ailments such as heart diseases, cancer, and diabetes, and the launch of the new therapeutics and rising funding of research and development (R&D) activities.
Regulatory compliance and safety standards
The pyrogen testing market growth is significantly driven by the implementation of stringent regulatory frameworks by health authorities such as the FOOD and DRUGS ADMINISTRATION in the United States and the EUROPEAN MEDICINE AGENCY in Europe. The Association for the Advancement of Medical Instrumentation (AAMI) ST72:2002/R2010, Bacterial Endotoxins-Test Methodologies, Routine Monitoring, and Alternatives to Batch Testing (AAMI ST72) are documents that describe the fundamental principles of the gel clot, photometric, and kinetic test methods, and recommend that appropriate components and finished products be tested for the presence of pyrogens and endotoxins. These regulations require rigorous safety testing of pharmaceuticals, medical devices, and biological products to ensure they are free of pyrogens, which can induce fever and pose severe risks to patients. As a result, manufacturers are incorporating pyrogen testing in their production processes.
Advancements in pharmaceuticals and biotechnology industries
The growth of the pharmaceutical and biotechnology sectors and the increasing biologics production is also creating a favorable pyrogen testing market outlook. Biologics, derived from living organisms are susceptible to contamination by pyrogens. According to IMARC GROUP, the global biologics market size reached US$ 349.6 Billion in 2023. Looking forward, the pyrogen testing market value is expected to reach US$ 699.5 Billion by 2032, exhibiting a growth rate (CAGR) of 7.8% during 2024-2032. As these industries expand, the requirement for sophisticated, reliable, and rapid pyrogen testing methods is also increasing. Moreover, this demand is leading to innovations in testing technologies, such as recombinant factor C (rFC) assays, which offer a synthetic alternative to traditional horseshoe crab blood-derived tests.
Developing healthcare infrastructure
The developing healthcare infrastructure in emerging economies and the increasing need for medical products that meet international safety standards, including pyrogen-free certifications is escalating the pyrogen testing demand. This expansion broadens the geographic market for pyrogen testing and compels local manufacturers to adopt advanced testing technologies to participate in global markets. Moreover, the development of healthcare systems and the increased healthcare spending is increasing the adoption and integration of advanced pyrogen testing processes. Besides, government authorities are also investing in the healthcare industry to promote public health. For instance, CENTER for DISEASE CONTROL and PREVENTION has awarded $3.2 billion to help state, local, and territorial jurisdictions across the United States strengthen their public health workforce and infrastructure. The $3.2 billion includes $3 billion from the AMERICAN RESCUE PLAN ACT for jurisdictions to recruit, retain, and train their workforce, including critical frontline public health workers such as epidemiologists, contact tracers, laboratory scientists, community health workers, and data analysts. The funding also includes $140 million from a new appropriation for jurisdictions to strengthen and revitalize their public health infrastructure.
Kits and reagents accounts for the majority of the market share
Kits and reagents are user-friendly allowing for quick setup and execution of tests by laboratory personnel without the need for extensive specialized training. This convenience leads to faster turnaround times in testing. Besides, pre-packaged kits and reagents are more cost-effective than in-house testing methods. The costs associated with R&D, validation, and quality control of self-made tests can be prohibitively high, especially for smaller companies. Moreover, companies are acquiring and merging with other companies and launching new advanced products to expand their pyrogen testing market share. For instance, in March 2021, PromegaCorp. launched XpressAmp Direct amplification reagent.
LAL tests hold the largest share of the industry
LAL tests are highly sensitive to bacterial endotoxins, capable of detecting them at very low levels. The sensitivity of these tests is crucial for ensuring the safety of pharmaceuticals and medical devices. Moreover, due to its proven reliability, the LAL test has become the standard method for endotoxin testing and is widely trusted by regulatory authorities and manufacturers. Besides, the LAL test is recognized and recommended by major regulatory bodies, including the U.S. Food and Drug Administration (FDA) and the European Pharmacopoeia. For more than 30 years, FDA has accepted the use of a Limulus Amoebocyte Lysate (LAL) test for endotoxins in lieu of the rabbit pyrogens test.
Pharmaceutical and biologics represents the leading market segment
The biologics sector is growing rapidly, driven by advancements in biotechnology and an increasing focus on personalized medicine. This expansion contributes to a greater demand for pyrogen testing as more biologics enter research pipelines and commercial production. Moreover, pharmaceutical and biotechnology companies are investing heavily in research and development to create new drugs and biological products which necessitate rigorous safety testing, including pyrogen testing, to ensure that these innovations are safe for human use. For instance, California-based Amgen Inc. invests heavily in its research and development activities and its expenditure for research and development was US$ 4.8 Billion, US$ 4.2 Billion, and US$ 4.1 Billion, for 2021, 2020, and 2019, respectively, as per its 2021 company annual report. These factors are expanding the use of these testing in pharmaceutical and biologics thus creating a positive pyrogen testing market forecast.
North America leads the market, accounting for the largest pyrogen testing market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for pyrogen testing.
North America boasts an advanced healthcare infrastructure with a strong emphasis on regulatory compliance and patient safety. This infrastructure supports and demands high standards for medical products, influencing the need for pyrogen testing to ensure the safety of pharmaceuticals and medical devices. Besides, the healthcare expenditure in North America is among the highest in the world, with significant spending allocated to health innovation, including safety testing. According to the CENTERS FOR MEDICARE & MEDICAID SERVICES, the United States healthcare spending grew 4 pending grew 4.1% to reach $4.5 Trillion in 2022, faster than the increase of 3.2% in 2021. Besides, retail prescription drug spending increased 8.4% to $405.9 Billion in 2022, a faster rate than in 2021 when spending increased by 6.8%. This financial capability is escalating the need for pyrogen testing, across the healthcare and pharmaceutical sectors.